ERAS Erasca, Inc. Common Stock Loading...

Loading chart...
Top Calls
Feed
Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
01:44
Jun 13
seedy19tron Biotech trader, L/S
The author maps out M&A scenarios in oncology but presents them as possibilities and research, not current positions or explicit trade calls.
ERAS
LOW
23:23
Jun 12
seedy19tron Biotech trader, L/S
Buy ERAS as the lower-cost RAS-side M&A alternative for large-cap acquirers (MRK, AZN, BMY) who miss out on RVMD; positioned as the "value option" in the same oncology combination-therapy consolidation wave.
ERAS 1ST
MED

About ERAS Analyst Coverage

Buzzberg tracks ERAS (Erasca, Inc. Common Stock) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (50%). 2 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: seedy19tron.